VITRO’s Post

Very pleased to see momelotinib, a drug discovered in Australia by a very talented team of scientists, is now approved in Australia. A new option for patients with myelofibrosis. https://lnkd.in/gFVEvFaC

When a cytokine storm arrives, it hits hard and quickly – even within 12-36 hours. That usually isn’t enough time to get the cytokine lab results back from external specialty send-outs. And that in turn makes developing new interventions that much harder At Kypha we know that timely cytokine analysis can deliver more accurate results and give healthcare providers and drug developers the information they need to make better decision faster. Kypha’s rapid test platform is designed specifically to address these challenges, and deliver better clinical trial data. Find out more at https://lnkd.in/er7rRyi9 #diagnostics #immunediagnostics #complement #cytokinestorm #rapidtest #cytokine

When a cytokine storm arrives, it hits hard and quickly – even within 12-36 hours. That usually isn’t enough time to get the cytokine lab results back from external specialty send-outs. And that in turn makes developing new interventions that much harder At Kypha we know that timely cytokine analysis can deliver more accurate results and give healthcare providers and drug developers the information they need to make better decision faster. Kypha’s rapid test platform is designed specifically to address these challenges, and deliver better clinical trial data.   Find out more at https://lnkd.in/eMnzviYj #diagnostics #immunediagnostics #complement #cytokinestorm #immunemonitoring

"Drug repurposing algorithms are revolutionizing how we find new uses for existing drugs, accelerating treatments for unmet needs. Curious how these models integrate safety data and real-world evidence—key for scaling to rare diseases and broader access.

Last week, we faced a tough decision at MayaBiotech We had two options for our new respiratory drug: Option A: Faster to market, higher profit margins. Option B: Took longer, cost more, but more effective. Seems like a no-brainer, right? Go for the quick win. But here's what we chose: Option B. Why? It all goes back to why we're here. MayaBiotech isn't just about making meds. It's about making a difference. Our team huddled up. We talked. We debated. We remembered our roots. My dad started this company with a vision:  "Make medicines that truly help people, no matter what." That vision still guides us today. So we chose the harder path. The longer road. The better medicine. Because at the end of the day, we're not just building a company. We're building a legacy of care. That's the MayaBioTech way. What about you? Ever had to choose between easy and right? How did it turn out?

📢 Webinar Alert: PreSTAR Tutorial Part 2 of 4 📢 💡 Price: $299 💡 Purchase here- https://lnkd.in/eipNh3-q This week we will be covering: -Submission Characteristics -Submission Purpose -Meeting Information -Product Description -Listing Product(s) -In Vitro Diagnostic Assay and Instrument Information -General Product Characteristics -Description -System/Kit Components and Accessories 👉 Don’t miss this chance to participate in this live webinar! #Webinar #MedicalDevice #DeNovo #FDAeSTAR #MedicalDeviceCompliance #eSTAR

We’ve come quite far from where we began at FogPharma — from inventing the basics of the Helicon technology to now being in the clinic with our first medicine, with four late discovery programs behind it; an expanded platform that seamlessly integrates highly innovative AI and experimental technologies; and programs spanning functional inhibitors, degraders, and radiopharmaceuticals. It’s in celebration of this rich history and thrilling future that we’re excited to unveil the next chapter in our storied history, as ✨ Parabilis Medicines ✨.   The word Parabilis draws on Greek and Latin etymologies to mean both ‘beyond what’s possible’ and also ‘obtainable’ — a perfect encapsulation of our drive to expand what is therapeutically possible for the treatment of serious diseases, and our commitment to ensuring our medicines reach and benefit patients globally. Learn more about what this new name means to us in today’s press release about the news: https://bit.ly/3C0HHX7 And explore our new website, at www.parabilismed.com, to find all-new details about our platform, our pipeline, and the exciting story of how we got here and where we’re going.  #ParabilisMedicines #CreatingExtraordinaryMedicines #Biotechnology

"Drug repurposing algorithms are revolutionizing how we find new uses for existing drugs, accelerating treatments for unmet needs. Curious how these models integrate safety data and real-world evidence—key for scaling to rare diseases and broader access.

Thoughts on this? >> Cytokinetics lifts curtain on Phase 3 aficamten data, commercial launch prep underway >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #pharmaceutical #biotech #productmarketing

𝐂𝐎𝐒𝐌𝐄𝐓𝐎𝐑𝐈𝐔𝐌 𝐁𝐀𝐑𝐂𝐄𝐋𝐎𝐍𝐀 𝟐𝟎𝟐𝟒 - 𝔻𝔸𝕐 𝟚 Do not hesitate to stop by our Booth 424 (Floor -1) to talk about #EFFICACYTESTING for active ingredients and end-products. Our CEO David González Fernández will be pleased to discuss about your needs and potential possibilities for in vitro bioassays and clinical testing in human volunteers. #Cosmetoirum2024 #Dermaclaim #EfficacyTesting #CosmeticScience